Procter & Gamble Health Ltd.
Snapshot View

5525.00 +23.30 ▲0.4%

05 August 2021, 04:00:00 P.M.
Volume: 461

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website https://www.pghealthindia.com
Financial Indicators
Market Cap 9,174.15 Cr.
Earnings per share (EPS) 115.53 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 47.84 Trailing Twelve Months Ending 2021-03
Industry PE 32.75 Trailing Twelve Months Ending 2021-03
Book Value / Share 398.00 Trailing Twelve Months Ending 2021-03
Price to Book Value 13.89 Calculated using Price: 5,526.80
Dividend Yield 4.16 Period Ending 2020-06
No. of Shares Subscribed 1.66 Cr. 16,599,382 Shares
FaceValue 10
Company Profile

Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967.  It was also the first Merck Group Company to go public in the year 1981.  Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.

On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.

Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.

Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.

Business area of the company

Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.

Brands of the company

  • Neurobion
  • Evion
  • Seven Seas
  • Nasivion
  • Polybion
  • Livogen

Awards and achievements

  • 2015-16: Merck Goa plant was awarded 1st prize in safety called “Gomant Sarvochcha Suraksha Puraskar”. This is consecutive 2nd time Merck Goa plant bagged 1st prize in safety. Prior to that Merck Goa plant bagged 2nd prize in safety “Gomant Uchcha Suraksha Puraskar” for two consecutive years.
  • 2016-17: Consumer activation done for Neurobion under ‘True Heroes’ campaign won laurels at the Global level to receive President’s Award in 2017.
  • 2017-18: Nasivion continued to be the Doctors’ trusted No. 1 Nasal Decongestant.
  • 2019-20: Neurobion bagged three awards viz. Nicholas Hall Marketing Excellence Award; CIMS Trusted Brand of the Year; and ABP News Brand Excellence Award.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.42%
1 Week
+2.33%
1 Month
-2.15%
3 Month
-12.48%
6 Month
-22.87%
1 Year
+25.26%
2 Year
+17.19%
5 Year
+689.06%
9 years 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2020-06
Return on Equity (%) 16.84 17.54 11.10 8.02 9.35 12.61 13.44 73.79 20.79
Return on Capital Employed (%) 25.30 26.14 17.53 12.36 14.54 18.35 21.79 80.76 29.01
Return on Assets (%) 9.57 8.16 6.71 4.67 3.92 5.48 6.52 40.93 10.82

Balance Sheet View Details

Particulars 9 years 2011-12 Rs. Cr. 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2020-06 Rs. Cr.
Shh. Funds 410 484 523 554 592 664 733 1,540 906
Non Curr. Liab. 13 338 13 390 395 399 431 495 667
Curr. Liab. 481 195 112 260 539 301 352 548 539
Minority Int.
Equity & Liab. 904 1,016 648 1,204 1,525 1,363 1,516 2,583 2,112
Non Curr. Assets 120 460 171 581 579 613 637 693 845
Curr. Assets 784 557 478 623 946 750 879 1,889 1,267
Misc. Exp. not W/O
Total Assets 904 1,016 648 1,204 1,525 1,363 1,516 2,583 2,112

Profit Loss View Details

Particulars 9 years 2011-12 Rs. Cr. 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2020-06 Rs. Cr.
Net Sales 590 687 798 867 940 993 698 1,288 1,356
Other Income 31 20 21 20 23 24 84 722 70
Total Income 621 707 819 888 963 1,017 782 2,010 1,426
Total Expenditure -517 -582 -721 -809 -856 -877 -628 -1,078 -1,042
PBIDT 104 126 98 79 107 140 154 932 384
Interest 0
Depreciation -8 -9 -10 -13 -23 -25 -19 -21 -29
Taxation -32 -38 -32 -23 -30 -36 -58 -79 -101
Exceptional Items 17 7
PAT 64 78 56 43 54 79 94 839 254

Cash Flow View Details

Particulars 9 years 2011-12 Rs. Cr. 2012-12 Rs. Cr. 2013-12 Rs. Cr. 2014-12 Rs. Cr. 2015-12 Rs. Cr. 2016-12 Rs. Cr. 2017-12 Rs. Cr. 2018-12 Rs. Cr. 2020-06 Rs. Cr.
Cash Fr. Operatn. 19 54 0 5 83 107 54 -130 235
Cash Fr. Inv. -9 -82 7 11 -68 -75 -48 1,270 165
Cash Fr. Finan. 0 -5 -17 -12 -15 -22 -30 -883
Net Change 10 -28 3 -1 4 17 -16 1,109 -483
Cash & Cash Eqvt 31 4 7 5 9 26 10 1,119 636

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 51.82 51.82 51.82 51.82 51.82 51.82 51.82 51.82 51.82
Public 48.18 48.18 48.18 48.18 48.18 48.18 48.18 48.18 48.18
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Disclosure: SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26 2018 With Respect To Disclosure Of Fund Raising By Issuance Of Debt Securities By Large Entities.
We refer to the SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018 with respect to fund raising by issuance of Debt Securities by large entities and disclosures thereof by such large entities. In this regard we wish to inform you that the Company does not fall under the criteria as specified in para 2.2 of the said SEBI Circular. Hence our Company does not classify as a Large Corporate under the framework provided in the above-mentioned circular for the financial year 2020-21.
Tue, 27 Jul 2021
Certificate Under Regulation 40(9) Of The SEBI Listing Regulations.
With reference to the above we are enclosing herewith Certificate under Regulation 40(9) of the SEBI Listing Regulations for the year ended June 30 2021.
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Procter & Gamble Health Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Wed, 04 Aug 2021
Opening at High Opening at High
Making Higher Highs for 3 days Making Higher Highs for 3 days
MFI Below 20 MFI Below 20
Tue, 03 Aug 2021
Closing Above Previous High Closing Above Previous High
MFI Below 20 MFI Below 20

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%